These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20930946)

  • 1. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
    Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
    Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
    Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
    Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
    Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
    Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
    Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
    Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
    Zeng Z; Gao ZL; Zhang ZP; Jiang HB; Yang CQ; Yang J; Xia XB
    Int J Mol Med; 2019 Jul; 44(1):103-114. PubMed ID: 31115482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
    Shaughnessy J
    Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
    Pandey MK; Sung B; Aggarwal BB
    Int J Cancer; 2010 Jul; 127(2):282-92. PubMed ID: 19937797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
    Kannappan R; Yadav VR; Aggarwal BB
    J Biol Chem; 2010 Oct; 285(43):33520-33529. PubMed ID: 20720018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
    Fan JL; Zhang J; Dong LW; Fu WJ; Du J; Shi HG; Jiang H; Ye F; Xi H; Zhang CY; Hou J; Wang HY
    Cell Death Dis; 2014 Mar; 5(3):e1126. PubMed ID: 24625985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
    Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
    PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
    Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
    Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
    Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
    Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
    Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
    Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.